Phase I/II trial of orteronel (TAK-700)-an investigational 17,20-lyase inhibitor-in patients with metastatic castration-resistant prostate cancer

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1335-1344

  Dreicer, Robert ^a   MacLean, David ^b   Suri, Ajit ^b   Stadler, Walter M ^d   Shevrin, Daniel ^e   Hart, Lowell ^g   MacVicar, Gary R ^f   Hamid, Omid ^h   Hainsworth, John ^j   Gross, Mitchell E ⁱ   Shi, Yuanjun ^b   Webb, Iain J ^c   Agus, David B ⁱ  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Takeda Pharmaceuticals International Co   (Japan)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g Sarah Cannon Research Institute/Florida Cancer Specialists   (United States)

^h Angeles Clinic and Research Institute   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j Section of Medical Oncology   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; AMINOGLUTETHIMIDE; AMINOTRANSFERASE; HEMOGLOBIN; KETOCONAZOLE; ORTERONEL; PRASTERONE SULFATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIACYLGLYCEROL LIPASE;

ACUTE KIDNEY FAILURE; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACTEREMIA; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPERAMYLASEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; LIMB PAIN; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MENINGIOMA; METASTASIS; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; MUSCLE SPASM; NAUSEA; OPEN STUDY; PAIN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY ARREST; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOMNOLENCE; SPINAL CORD COMPRESSION; SUPRAVENTRICULAR PREMATURE BEAT; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

AGED; AGED, 80 AND OVER; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NAPHTHALENES; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; STEROID 17-ALPHA-HYDROXYLASE; TREATMENT OUTCOME;

EID: 84895785730     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2436     Document Type: Article

References (24)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1: 293-7.
2. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol 2010;17 (suppl 2):S72-9.
3. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 2011;18: R175-82.
4. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407-15.
5. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8:440-8.
6. Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castrationresistant prostate cancer. Br J Cancer 2009;100:671-5.
7. Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol 2012;4:167-78.
8. Kaku T, Hitaka T, Ojida A, Matsunaga N, Adachi M, Tanaka T, et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011;19: 6383-99.
9. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004;25:947-70.
10. Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 2011;125:23-31.
11. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
12. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de SP, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.
13. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. ASCO Meeting Abstracts 2012;30 (suppl):LBA1 (abstr).
14. Yamaoka M, Hara T, Hitaka T, Kaku T, Takeuchi T, Takahashi J, et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol 2012;129:115-28.
15. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
17. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920-8.
18. Scher HI, Heller G, Molina A, Kheoh TS, Attard G, Moreira J, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebocontrolled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. ASCO Meeting Abstracts 2011;29 (suppl):LBA4517 (abstr).
19. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
20. Stewart PM, Krone NP. The adrenal cortex. In:Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. Williams textbook of endocrinology. 12th ed. Philadelphia, PA: Sanders Elsevier; 2011. p. 479-544.
21. MacLean DB, Stadler WM, Shevrin D, Hart L, Wang J, Webb I, et al. Selective inhibition of androgen synthesis by orteronel (TAK-700), an investigational 17,20-lyase inhibitor, in men with metastatic castrate resistant prostate cancer (mCRPC). Poster presented at the Endocrine Society's 94th Annual Meeting & Expo Houston, Texas, USA 2012.
22. Heng DY, Chi KN. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol 2006;13:3335-9.
23. George DJ, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, et al. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): updated results of a phase II study. ASCO Meeting Abstracts 2012;30 (suppl):4549 (abstr).
24. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.